Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 301 to 350 of 373

Guidance and quality standards awaiting development
Title	Type
Supporting independent living and preventing isolation in adults of working age with social care needs	Quality standard
Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]	Technology appraisal guidance
Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]	Technology appraisal guidance
Surovatamig for treating relapsed or refractory follicular lymphoma after 2 or more treatment lines [TSID12354]	Technology appraisal guidance
Survodutide for managing overweight and obesity [ID6752]	Technology appraisal guidance
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]	Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]	Technology appraisal guidance
Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]	Technology appraisal guidance
Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]	Technology appraisal guidance
Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [ID6749]	Technology appraisal guidance
Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]	Technology appraisal guidance
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Technologies for the detection of Hepatocellular Carcinoma	HealthTech guidance
Technologies to improve detection of endometrial cancer	HealthTech guidance
Technology for cancer case finding using primary care records	HealthTech guidance
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]	Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance
Thyroid disease	Quality standard
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]	Technology appraisal guidance
Tildrakizumab for treating active psoriatic arthritis [TSID12218]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tinnitus	Quality standard
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]	Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]	Technology appraisal guidance
Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]	Technology appraisal guidance
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [ID6733]	Technology appraisal guidance
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]	Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]	Technology appraisal guidance
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]	Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]	Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]	Technology appraisal guidance
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]	Technology appraisal guidance
Tocilizumab for treating systemic sclerosis [ID1396]	Technology appraisal guidance
Topical tapinarof for treating atopic dermatitis in people 2 years and over [ID6713]	Technology appraisal guidance
Topical tapinarof for treating mild to severe plaque psoriasis [ID6712]	Technology appraisal guidance
Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]	Technology appraisal guidance
Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids	HealthTech guidance
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]	Technology appraisal guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]	Technology appraisal guidance
Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]	Technology appraisal guidance
Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]	Technology appraisal guidance
Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]	Technology appraisal guidance
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]	Technology appraisal guidance
Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]	Technology appraisal guidance
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]	Technology appraisal guidance
Troriluzole for spinocerebellar ataxia [ID6456]	Technology appraisal guidance
Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]	Technology appraisal guidance
Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [ID6755]	Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781]	Technology appraisal guidance
Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]	Technology appraisal guidance

Results per page

10
25
50
All